29 related articles for article (PubMed ID: 28096652)
1. Corrigendum: Korean treatment recommendations for patients with axial spondyloarthritis.
Seo MR; Yeo J; Park JW; Lee YA; Lee JH; Kang EH; Ji SM; Kwon SR; Kim SK; Kim TJ; Kim TH; Kim HW; Park MC; Shin K; Lee SH; Lee EY; Cha HS; Shim SC; Yoon Y; Lee SH; Lim JH; Baek HJ
J Rheum Dis; 2024 Jan; 31(1):62-63. PubMed ID: 38164191
[TBL] [Abstract][Full Text] [Related]
2. Erratum for "Functional Imaging of Mitochondria in Age-Related Macular Degeneration Using Flavoprotein Fluorescence".
Ophthalmic Surg Lasers Imaging Retina; 2023 Dec; 54(12):732. PubMed ID: 38113366
[No Abstract] [Full Text] [Related]
3. Erratum: Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum].
Clin Interv Aging; 2016; 11():775. PubMed ID: 27358559
[TBL] [Abstract][Full Text] [Related]
4. Erratum: Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum].
Clin Ophthalmol; 2017; 11():355. PubMed ID: 28243059
[TBL] [Abstract][Full Text] [Related]
5. Erratum: A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum].
Clin Ophthalmol; 2017; 11():303. PubMed ID: 28223773
[TBL] [Abstract][Full Text] [Related]
6. Erratum: Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum].
Clin Ophthalmol; 2017; 11():619. PubMed ID: 28435211
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum.
Paediatr Child Health; 2015; 20(8):466-7. PubMed ID: 26744561
[TBL] [Abstract][Full Text] [Related]
8. Erratum: Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum].
Clin Ophthalmol; 2017; 11():95. PubMed ID: 28096652
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing.
Szabo SM; Hedegaard M; Chan K; Thorlund K; Christensen R; Vorum H; Jansen JP
Curr Med Res Opin; 2015 Nov; 31(11):2031-42. PubMed ID: 26296050
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
Mitchell P
Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
[TBL] [Abstract][Full Text] [Related]
12. A safety evaluation of ranibizumab in the treatment of age-related macular degeneration.
Gibson JM; Gibson SJ
Expert Opin Drug Saf; 2014 Sep; 13(9):1259-70. PubMed ID: 25091039
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
